These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 337773)

  • 21. [Disappearance of the disordered postural regulation of cerebral circulation by the addition of benserazide in parkinsonism treated with L-dopa].
    Boismare F; Samson M; Pouliquen A; Hacpille L
    Therapie; 1976; 31(5):615-22. PubMed ID: 1013953
    [No Abstract]   [Full Text] [Related]  

  • 22. KR 339 in the treatment of Parkinsonian tremor.
    Iivanainen M
    Acta Neurol Scand; 1974; 50(4):469-77. PubMed ID: 4604665
    [No Abstract]   [Full Text] [Related]  

  • 23. Nomifensine in parkinsonism.
    Park DM; Findley LJ; Teychenne PF
    Br J Clin Pharmacol; 1977; 4Suppl 2(Suppl 2):185S-186S. PubMed ID: 334222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abnormal involuntary movements in relation to anticholinergics and levodopa therapy.
    Birket-Smith E
    Acta Neurol Scand; 1975 Aug; 52(2):158-60. PubMed ID: 1155032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.
    Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C
    Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New strategies in the management of Parkinson's disease: a biological approach using a phospholipid precursor (CDP-choline).
    Agnoli A; Ruggieri S; Denaro A; Bruno G
    Neuropsychobiology; 1982; 8(6):289-96. PubMed ID: 7162583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Audit of the drug treatment of Parkinson's disease in general practice.
    Wilson JA; Murray TS
    J R Coll Gen Pract; 1985 Jun; 35(275):276-8. PubMed ID: 4032354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evaluation of the effectiveness of combined (L-dopa + Jumex) therapy based on a multicentric double blind study].
    Tariska I; Gallai M
    Orv Hetil; 1983 Sep; 124(38):2309-14. PubMed ID: 6415577
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
    Brannan T; Yahr MD
    Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
    Libman I; Gawel MJ; Riopelle RJ; Bouchard S
    Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Bornaprine in the treatment of parkinsonian tremor].
    Piccirilli M; D'Alessandro P; Testa A; Piccinin GL; Agostini L
    Riv Neurol; 1985; 55(1):38-45. PubMed ID: 3895365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Evaluation of combined L-dopa-cyproheptadine therapy of patients with Parkinson's disease].
    Fodor M; Solymosi L; Szántó J
    Orv Hetil; 1980 Jul; 121(27):1631-6. PubMed ID: 7005809
    [No Abstract]   [Full Text] [Related]  

  • 33. Plasma concentrations of L-dopa and 3-methoxydopa and improvement in clinical ratings and motor performance in patients with Parkinsonism treated with L-dopa alone or in combination with amantadine.
    Pilling JB; Baker J; Iversen LL; Iversen SD; Robbins T
    J Neurol Neurosurg Psychiatry; 1975 Feb; 38(2):129-35. PubMed ID: 1097598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of a dihydromorphanthridine derivative in Parkinson's patients treated with L-dopa. A preliminary report.
    Wycis HT
    Confin Neurol; 1972; 34(2):130-5. PubMed ID: 4666056
    [No Abstract]   [Full Text] [Related]  

  • 35. Antiparkinsonian agents and long-term neuroleptic treatment. Effect of G 31.406, orphenadrine, and placebo on parkinsonism, schizophrenic symptoms, depression and anxiety.
    Gerlach J; Rasmussen PT; Hansen L; Kristjansen P
    Acta Psychiatr Scand; 1977 Apr; 55(4):251-60. PubMed ID: 324238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A double-blind comparison of levodopa, Madopa, and Sinemet in Parkinson disease.
    Diamond SG; Markham CH; Treciokas LJ
    Ann Neurol; 1978 Mar; 3(3):267-72. PubMed ID: 352236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dopaminergic agonist Ro 8-4650 in Parkinson's disease. I. Patients treated with dopa.
    Birket-Smith E; Bøttcher J; Dupont E; Holm P; Jensen JP; Kristensen O; Køhler O; Mikkelsen B
    Acta Neurol Scand; 1978 Jul; 58(1):74-6. PubMed ID: 360759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease.
    Mark MH; Sage JI
    Ann Clin Lab Sci; 1989; 19(2):101-6. PubMed ID: 2665626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Antiparkinsonian drugs].
    Rascol A; Montastruc JL; Rascol O
    Rev Prat; 1989 Mar; 39(8):663-9. PubMed ID: 2567051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tremor in Parkinson disease: acute response to oral levodopa.
    Tedeschi G; Sasso E; Marshall RW; Bonavita V
    Ital J Neurol Sci; 1990 Jun; 11(3):259-63. PubMed ID: 2201664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.